



NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE
Thomas Farley, MD, MPH
Commissioner

Jane R. Zucker, MD, MSc
Assistant Commissioner
jzucker@health.nyc.gov

Bureau of Immunization
2 Lafayette Street, 19th Fl.
New York, NY 10007

****DISTRIBUTE TO ALL CLINICAL AND OFFICE STAFF ****

February 25, 2011

Dear Colleague:

The Advisory Committee on Immunization Practices (ACIP) has released the 2011 Recommended Immunization Schedules for Children, Adolescents and Adults. These updated schedules and information about the changes are available at www.cdc.gov/vaccines/recs/schedules/default.htm

We would like to highlight the major changes and clarifications to the schedules:

For children and adolescents:

- **PCV13:** A single supplemental dose of PCV13 is recommended for all children 14-59 months of age who have completed an age-appropriate PCV7 series. Older children and teens with functional or anatomic asplenia, HIV infection, immunocompromising conditions, cochlear implant or CSF leak should also receive a dose of PCV13.
- **Tdap:** Children 7 through 10 years of age who are not fully immunized against pertussis should receive a single dose of Tdap vaccine. Adolescents 11-18 years who have not received Tdap should receive a dose. If Tdap is indicated, it should be administered regardless of the interval since the last Td-containing vaccine.
- **MCV4:** All persons 2 through 18 years of age with functional or anatomical asplenia, persistent complement component deficiencies and HIV infection should receive a 2-dose primary series with the doses administered 8 weeks apart.

For adults:

- **Tdap:** Persons 65 years of age or older who have close contact with an infant younger than 12 months of age should receive Tdap. All persons 65 years of age or older may receive Tdap. If Tdap is indicated, it should be administered regardless of the interval since the last Td-containing vaccine.
- **MCV4:** All persons 18 through 55 years of age with functional or anatomical asplenia, persistent complement component deficiencies and HIV infection should receive a 2-dose primary series with the doses administered 8 weeks apart.

Recommendations from ACIP are considered the standard of immunization practice even if not included in the package insert. Vaccine should be administered in accordance with these new recommendations.

For additional details about the revised schedules and changes see www.cdc.gov/vaccines/recs/schedules/downloads/child/mmwr-child-schedule.pdf and www.cdc.gov/vaccines/recs/schedules/downloads/adult/mmwr-adult-schedule.pdf

The Citywide Immunization Registry (CIR) is being updated to reflect these new recommendations.

For questions related to vaccine supply, the Vaccines for Children Program or about the CIR, e-mail nycimmunize@health.nyc.gov or call 212-676-2323. For professional or technical questions call the Bureau of Immunization at 212-676-2259. Thank you.

Sincerely,

Jane R. Zucker, MD, MSc